Researchers reviewed recent preclinical and early clinical work advancing CAR‑T and CAR‑NK approaches against acute myeloid leukemia (AML). The report synthesizes new antigen targets, engineering strategies to limit off‑tumor toxicity, and manufacturing considerations for both T and NK platforms. Authors highlight CAR‑NK’s potential advantages—shorter persistence and allogeneic use—while acknowledging AML’s antigen heterogeneity and immunosuppressive microenvironment remain major obstacles. The review aggregates translational data and trial designs now moving into first‑in‑human testing. For developers and investors: the field is rapidly diversifying beyond classic CAR‑T constructs; AML is emerging as a focal area for next‑generation cell therapies and combination strategies with checkpoint modulation or targeted agents.